Summary & Overview
HCPCS J0288: Amphotericin B Cholesteryl Sulfate Complex Injection, 10 mg
HCPCS Level II code J0288 denotes an intravenous injection of amphotericin B cholesteryl sulfate complex, 10 mg, an antifungal therapy used in serious systemic fungal infections. This national-level billing code captures utilization of a specialized parenteral medication often administered in inpatient settings or infusion centers and has implications for hospital pharmacy management, payer coverage policies, and clinical formularies.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find an overview of billing and clinical context for J0288, typical sites of service where the product is administered, and what to expect in payer coverage patterns. The publication also summarizes common modifiers associated with HCPCS billing and highlights areas where policy updates or coverage limitations can affect access.
The report provides concise benchmarks on utilization and reimbursement structures, national policy considerations relevant to antifungal injectables, and clinical context for use of amphotericin B cholesteryl sulfate complex. It is intended as a practical reference for coding staff, clinicians, and policy analysts seeking a clear understanding of the code’s clinical purpose, billing environment, and payer landscape. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0288 represents an injection of amphotericin B cholesteryl sulfate complex, 10 mg. This code is used to bill for administration of the specified antifungal formulation.
-
Service type: Parenteral antifungal therapy (intravenous injection)
-
Typical site of service: Hospital inpatient or outpatient infusion center, emergency department, or other facility capable of intravenous medication administration
Clinical & Coding Specifications
Clinical Context
A hospitalized adult patient with invasive fungal infection unresponsive or intolerant to conventional amphotericin B preparations is prescribed J0288 (injection, amphotericin B cholesteryl sulfate complex, 10 mg). Typical scenario: a patient in an inpatient infectious disease setting or infusion center with severe systemic mycoses (e.g., cryptococcosis, invasive candidiasis, invasive aspergillosis, mucormycosis) who requires parenteral antifungal therapy. The clinical workflow includes: medication order entry by the treating infectious disease physician or hospitalist, review of renal function and electrolytes by nursing/pharmacy, preparation of the amphotericin B cholesteryl sulfate complex by pharmacy under sterile compounding conditions, verification of dose and infusion rate, administration via peripheral or central IV line by an experienced nurse, monitoring for infusion-related reactions (fever, chills, hypotension), and daily assessment of renal function and electrolytes to guide ongoing dosing and duration. Typical sites of service are inpatient hospital (acute care), outpatient infusion center, and specialty clinics with IV infusion capabilities. Patient monitoring may include premedication for infusion reactions, fluid and electrolyte management, and coordination with antimicrobial stewardship and pharmacy for therapeutic decisions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |